Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Core Insights - Terns Pharmaceuticals announced unprecedented efficacy data from the CARDINAL trial of TERN-701, showing a 64% major molecular response (MMR) achievement by 24 weeks in a refractory chronic myeloid leukemia (CML) patient population [1][3] - The company will present these findings at the 67th American Society of Hematology (ASH) Annual Meeting on December 8, 2025, and will host an investor update call following the presentation [1][7] Efficacy Data - The CARDINAL trial reported a cumulative MMR rate of 75% (24 out of 32 patients) by 24 weeks, with 64% (14 out of 22) achieving MMR and 100% (10 out of 10) maintaining MMR [5] - In difficult-to-treat patient subgroups, MMR rates were 69% (11 out of 16) for those with lack of efficacy to the last tyrosine kinase inhibitor (TKI), 60% (6 out of 10) for patients who had prior asciminib, and 67% (8 out of 12) for those with prior asciminib/ponatinib/investigational TKI [5] Patient Population - The enrolled patients had heavily pretreated, refractory disease, with a median of 3 prior TKIs; 35% had 4 or more prior TKIs [5] - 64% of patients discontinued their last TKI due to lack of efficacy, and 13% had BCR::ABL1 mutations [5] Safety Profile - TERN-701 demonstrated an encouraging safety profile, with no dose-limiting toxicities observed during the dose escalation phase [10] - The majority (74%) of treatment-emergent adverse events (TEAEs) were low grade, with the most common TEAEs being diarrhea (22%), headache (18%), and nausea (16%) [10] Upcoming Events - The oral presentation at ASH will be led by Dr. Elias Jabbour and is scheduled for December 8, 2025, from 2:45 to 3:00 PM ET [6] - Following the presentation, Terns will host a conference call and webcast for investors at 4:30 PM ET to discuss the data and next steps in the development of TERN-701 [7]